Advertisement

Circulating extracellular vesicles as a predictive biomarker for acute graft-versus-host disease

Published:November 15, 2022DOI:https://doi.org/10.1016/j.exphem.2022.11.004

      Highlights

      • EV have been described as biomarkers of cellular damage and activation, and their role in aGVHD has not been established.
      • TEV counts were associated with a higher CI of grade II–IV aGVHD.
      • In patients exposed to RIC, stronger associations of both high TEV and EryEV counts with aGVHD were observed.
      • Cell-derived EV counts at engraftment are associated with aGVHD, and their role as a biomarker may assist in treatment decisions in this scenario.
      The diagnosis and management of graft-versus-host disease (GVHD) have remained important challenges in allogeneic stem cell transplantation (allo-SCT). Novel diagnostic methods and therapeutic interventions are needed to further improve on patient outcomes. Extracellular vesicles (EV) are microvesicles formed by the inversion of the phospholipid bilayer of different cellular subtypes and have been described as biomarkers of cellular damage, activation, and intercellular signaling in numerous clinical scenarios. We studied the association between the levels of EV and the incidence of acute GVHD (aGVHD). Forty patients undergoing allo-SCT for hematological malignancies had their plasma collected at neutrophil engraftment. Using flow cytometry combined with fluorescent beads, the total circulating EV count (TEV) was established with annexin V positivity; CD61 positivity was used for platelet-derived EV (PEV), and CD235 positivity, for erythrocyte-derived EV (EryEV). TEV counts greater than 516/μL were associated with a higher cumulative incidence (CI) of grade II to IV aGVHD (54% vs. 21%; p = 0.02), as were EryEV counts above 357 /μL (CI of aGVHD: 59% vs. 26%; p = 0.04). In patients who are exposed to reduced intensity conditioning (RIC), stronger associations of both high TEV and EryEV counts with aGVHD were observed (77% vs. 22%; p = 0.003 and 89% vs. 27%; p = 0.002, respectively). PEV levels were not associated with the risk of aGVHD. Our data suggest that the measurement of cell-derived EV at engraftment can be used as a preemptive biomarker for acute GVHD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Experimental Hematology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hamilton BK.
        Updates in chronic graft-versus-host disease.
        Hematology Am Soc Hematol Educ Program. 2021; 2021: 648-654
        • Martinez-Cibrian N
        • Zeiser R
        • Perez-Simon JA.
        Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions.
        Blood Rev. 2021; 48 (Epub 2020 Dec 26)100792https://doi.org/10.1016/j.blre.2020.100792
        • Weissinger EM
        • Metzger J
        • Dobbelstein C
        • Wolff D
        • Schleuning M
        • Kuzmina Z
        • et al.
        Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation.
        Leukemia. 2014; 28: 842-852
        • Pratta M
        • Paczesny S
        • Socie G
        • et al.
        A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.
        Br J Haematol. 2022; 198: 729-739
        • Paczesny S.
        Discovery and validation of graft-versus-host disease biomarkers.
        Blood. 2013; 121: 585-594
        • Zeiser R.
        Advances in understanding the pathogenesis of graft-versus-host disease.
        Br J Haematol. 2019; 187 (Epub 2019 Oct 6): 563-572https://doi.org/10.1111/bjh.16190
        • György B
        • Szabó TG
        • Pásztói M
        • Pál Z
        • Misják P
        • Aradi B
        • et al.
        Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles.
        Cell Mol Life Sci. 2011; 68: 2667-2688
        • Wu Z-H
        • Ji C-L
        • Li H
        • et al.
        Membrane microparticles and diseases.
        Eur Rev Med Pharmacol Sci. 2013; 17: 2420-2427
        • a Hargett L
        • NN Bauer
        On the origin of microparticles: From ‘platelet dust’ to mediators of intercellular communication.
        Pulm Circ. 2013; 3: 329-340
        • Leonetti D
        • Reimund J-M
        • Tesse A
        • et al.
        Circulating microparticles from Crohn's disease patients cause endothelial and vascular dysfunctions.
        PLoS One. 2013; 8: e73088
        • Parker B
        • Al-Husain A
        • Pemberton P
        • et al.
        Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus.
        Ann Rheum Dis. 2014; 73: 1144-1150
        • Crossland R
        • Perutelli F
        • Bogunia-Kubik K
        • Mooney N.
        Potential novel biomarkers in chronic graft-versus-host disease.
        Front. Immunol. 2020; 11: 1-16
        • Pihusch V
        • Rank A
        • Steber R
        • Pihusch M
        • Pihusch R
        • Toth B
        • et al.
        Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients.
        Transplantation. 2006; 81: 1405-1409
        • Zhang R
        • Wang X
        • Hong M
        • Luo T.
        Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versushost disease following allogeneic hematopoietic stem cell transplantation.
        Oncotarget. 2017; 8: 23360-23375
        • Rank A
        • Nieuwland R
        • Toth B
        • Pihusch V
        • Delker R
        • Hiller E
        • et al.
        Microparticles for diagnosis of graft-versus-host disease after allogeneic stem transplantation.
        Transplantation. 2011; 92: 244-250
        • Muñoz LE
        • Lauber K
        • Schiller M
        • Manfredi AA
        • Herrmann M.
        The role of defective clearance of apoptotic cells in systemic autoimmunity.
        Nat Rev Rheumatol. 2010; 6: 280-289
        • Meziani F
        • Delabranche X
        • Asfar P
        • Toti F.
        Bench-to-bedside review: circulating microparticles—a new player in sepsis?.
        Crit Care. 2010; 14: 236
        • Lacroix R
        • Robert S
        • Poncelet P
        • et al.
        Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop.
        J. Thromb Haemost. 2010; 8: 2571-2574
        • Nielsen MH
        • Beck-Nielsen H
        • Andersen MN
        • Handberg A.
        A flow cytometric method for characterization of circulating cell-derived microparticles in plasma.
        J Extracell Vesicles. 2014; 3: 1-12
        • Mullier F
        • Bailly N
        • Chatelain C
        • Dogné JM
        • Chatelain B.
        Calibration for the measurement of microparticles: needs, interests, and limitations of calibrated polystyrene beads for flow cytometry-based quantification of biological microparticles.
        J Thromb Haemost. 2011; 9 (–82): 1679-1681
        • Trummer A
        • De Rop C
        • Stadler M
        • Ganser A
        • Buchholz S.
        P-selectin glycoprotein ligand-1 positive microparticles in allogeneic stem cell transplantation of hematologic malignancies.
        Exp Hematol. 2011; 39: 1047-1055
        • Nomura S
        • Ishii K
        • Inami N
        • et al.
        Evaluation of angiopoietins and cell-derived microparticles after stem cell transplantation.
        Biol Blood Marrow Transplant. 2008; 14: 766-774
        • Rank A
        • Nieuwland R
        • Delker R
        • et al.
        Surveillance of megakaryocytic function by measurement of CD61-exposing microparticles in allogeneic hematopoietic stem cell recipients.
        Clin Transplant. 2011; 25: E233-E242
        • Lia G
        • Brunello L
        • Bruno S
        • Carpanetto A
        • Omede P
        • et al.
        Extracellular vesicles as potential biomarkers of acute graft-vs.-host-disease.
        Leukemia. 2018; 32: 765-773
        • Lia G
        • Di Vito C
        • Bruno S
        • Tapparo M
        • et al.
        Extracellular vesicles as biomarkers of acute graft-vs.-host disease after haploidentical stem cell transplantation and post-transplant cyclophosphamide.
        Front Immunol. 2022; : 12
        • Nagasawa M
        • Mitsuiki N
        • Yanagimachi M
        • Yamamoto M.
        Utility of novel T-cell-specific extracellular vesicles in monitoring and evaluation of acute GVHD.
        Int. J. Hematol. 2021; 113: 910-920
        • Przepiorka D
        • Weisdorf D
        • Martin P
        • et al.
        1994 Consensus conference on acute GVHD grading.
        Bone Marrow Transplant. 1995; 15: 825-828
        • Gonçalves MV
        • Yamamoto M
        • Kimura EYS
        • et al.
        Low counts of plasmacytoid dendritic cells after engraftment are associated with high early mortality after allogeneic stem cell transplantation.
        Biol Blood Marrow Transplant. 2015; : 1-7
        • Bogunia-Kubik K
        • Mizia S
        • Gronkowska A
        • et al.
        CCR5 gene polymorphism affects the risk of GvHD after haematopoietic stem cell transplantation from an unrelated donor.
        Br J Haematol. 2015; 171: 285-288
        • Ponce DM
        • Hilden P
        • Mumaw C
        • et al.
        High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
        Blood. 2015; 125 (199–105)
        • Fuji S
        • Kim S-W
        • Fukuda T
        • et al.
        Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
        Biol Blood Marrow Transplant. 2008; 14: 510-517
        • Ayers L
        • Kohler M
        • Harrison P
        • et al.
        Measurement of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay.
        Thromb Res. 2011; 127: 370-377
        • Yuana Y
        • Bertina RM
        • Osanto S.
        Pre-analytical and analytical issues in the analysis of blood microparticles.
        Thromb Haemost. 2011; 105 (396–08)
        • Dey-Hazra E
        • Hertel B
        • Kirsch T
        • et al.
        Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing.
        Vasc Health Risk Manag. 2010; 6: 1125-1133
        • Nielsen MH
        • Beck-Nielsen H
        • Andersen MN
        • Handberg A.
        A flow cytometric method for characterization of circulating cell-derived microparticles in plasma.
        J Extracell Vesicles. 2014; 3: 1-12
        • Lim HC
        • Soneji S
        • Pálmason R.
        • et al.
        Development of acoustically isolated extracellular plasma vesicles for biomarker discovery in allogeneic hematopoietic stem cell transplantation.
        Biomark Res. 2021; 9: 6